Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trialControlled Trial Published on 2022-02-212023-06-15 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, [키워드] AZD1222 boost ChAdOx1 nCoV-19 COVID-19 Fractional dose immunogenicity intradermal route Safety SARS-CoV-2 third dose [DOI] 10.1016/j.vaccine.2022.02.019 PMC 바로가기 [Article Type] Controlled Trial
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article암 환자를 위한 항 SARS-CoV-2 백신 3차 접종: 체액 반응을 모니터링해야 합니까? 입장 기사Review Published on 2022-02-012022-09-12 Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition Administered anti-S anti-SARS-CoV-2 anti-SARS-CoV-2 vaccines anti-spike antibodies antibody appear assist binding booster booster dose Cancer clinical trial Comorbidity COVID-19 death dosage dose Epidemic Evidence General population helping higher risk humoral Humoral response Immunocompromised patient incidence rates less mandatory monitoring oncologist outlined Patient patient population Patients with cancer recommendation SARS-CoV-2 Seroconversion serological severe coronavirus disease suggested Taking third dose titre undergo vaccination Vaccine waning immunity [DOI] 10.1016/j.ejca.2021.12.011 PMC 바로가기 [Article Type] Review
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up화학 요법의 유무에 관계없이 PD-1/PD-L1 억제제로 치료받은 암 환자에서 BNT162B2 항 -SARS-COV-2 백신의 전체 과정 후 체액 및 세포 면역 반응의 분석 : 6 개월의 추적 관찰 후 업데이트Article Published on 2022-02-012022-08-31 Journal: ESMO open [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] Analysis analyzed anti-SARS-CoV-2 Anti-spike antibody B.1.1 strain BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine BNT162b2 vaccine Cancer cancer patient Cancer patients Cell cell death cell-mediated immune cell-mediated immune response Cellular immune response chemo-immunotherapy Chemotherapy Concentration correlation Course COVID-19 vaccine dose enrolled enzyme enzyme-linked immunosorbent evaluated Follow-up highlight humoral IFN-γ immune response immunogenicity Immunoglobulin Immunoglobulin G Immunotherapy inhibitor inhibitors interferon-γ interquartile range IQR median mononuclear cells naïve naïve subjects Neutralizing neutralizing antibody of BNT162b2 Patient PD-1/PD-L1 inhibitors Peripheral blood Peripheral blood mononuclear cells previous study programmed cell death programmed cell death protein Protein quantification quantified reduction reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination serum samples significant decrease significantly lower spike-specific T-cell spike-specific T-cell response subject subjects Support T-cell Response the vaccine third dose treated triggering vaccination Vaccine was used [DOI] 10.1016/j.esmoop.2021.100359 PMC 바로가기 [Article Type] Article
Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare WorkersArticle Published on 2022-01-302022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Administered All participant Analysis anti-Spike IgG B cell baseline blood sample booster booster dose Cellular immune response cellular immunity ChAdOx1 ChAdOx1 nCoV-19 CoronaVac COVID-19 COVID-19 pandemic Decline dose early phase ELISA ELISPOT evaluate function healthcare healthcare worker humoral Humoral immunity IgG Immunity immunogenicity indicated neutralizing antibody PROTECT provided random SARS-CoV-2 significantly higher stratified T cell third dose Twenty participant vaccination Vaccine Vaccines were measured worker [DOI] 10.3390/vaccines10020217 PMC 바로가기 [Article Type] Article
Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-AnalysisArticle Published on 2022-01-092022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% confidence interval anti-SARS-CoV-2 vaccine Antibody Response antibody response rate appear COVID-19 COVID-19 vaccine demonstrated dose Efficacy Efficacy and safety evaluated inclusion criteria linear mRNA vaccine occurred Patient patients performed proportion Random-effects models Randomized controlled trial recipient recipients reduced reported retrospective review Safe Safety safety profile second dose serologic seronegative severe adverse event Solid solid organ solid organ transplant Solid organ transplant recipients systemic the SARS-CoV-2 third dose Transplant Vaccine vaccine dose Vaccines Web of Science [DOI] 10.3390/vaccines10010095 PMC 바로가기 [Article Type] Article
Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional StudyArticle Published on 2022-01-072022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI acceptance age antibody Associated factors belief benefit booster Characteristics China Chinese collected conducted country COVID-19 COVID-19 infection COVID-19 susceptibility COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines cross-sectional declining distribution dose Factor General population Health help individual information initial International Intervention knowledge knowledge score less multivariable logistic regression Participants provided receive Sinovac susceptibility the vaccine third dose vaccination Vaccine Vaccines variant were used [DOI] 10.3390/vaccines10010089 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated VaccineArticle Published on 2022-01-062022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] acute respiratory syndrome addition administration adverse events anti-RBD AZD1222 binding domain BNT162b2 booster booster dose booster response booster vaccination clinical trial CoronaVac coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose doses healthcare healthy IgA IgG immunogenicity Inactivated vaccine indicated individual Infection mRNA mRNA vaccine neutralization activity outbreak pandemic Patient platform proportion RBD receiving Safe Safety SARS-CoV-2 secreting Serious Adverse Events serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significant increase Spread T-cell Response third dose vaccination Vaccines variant vector Viral vector Viral vector vaccine wild-type [DOI] 10.3390/vaccines10010086 PMC 바로가기 [Article Type] Article
No further delays in offering booster doses in countries experiencing a major resurgence of COVID-19Article Published on 2021-12-292023-06-19 Journal: Journal of Travel Medicine [Category] Fulltext, SARS, [키워드] booster shot COVID mRNA third dose Vaccine [DOI] 10.1093/jtm/taab187 PMC 바로가기
COVID-19 Vaccine Booster: To Boost or Not to BoostReview Published on 2021-10-282022-10-30 Journal: Infectious Disease Reports [Category] COVID-19, [키워드] acute respiratory syndrome booster booster dose Care CDC center Control coronavirus Coronavirus 2019 coronavirus disease country COVID-19 COVID-19 vaccine COVID-19 vaccines develop Developing dose effective vaccine exceptional Health Immunity immunization Immunocompromised immunocompromised individual pandemic Population prevention Safe SARS-CoV-2 SARS-CoV-2 viral Strains third dose vaccination Vaccine vaccine inequity viral strain waning immunity [DOI] 10.3390/idr13040084 PMC 바로가기 [Article Type] Review
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody DeficienciesSARS-CoV-2 감염에 의해 유도된 B 세포 반응은 1차 항체 결핍에서 BNT162b2 백신에 의해 촉진됩니다Article Published on 2021-10-272022-09-12 Journal: Cells [Category] MERS, SARS, 진단, [키워드] analyzed anti-Spike IgG Antibody Response Atypical B cell response BNT162b2 BNT162b2 vaccine Cell classical common variable immunodeficiencies convalescent convalescent patient COVID-1 COVID-19 pandemic CVID deficiency dose IgG immune response immunization immunized immunodeficiency immunological induced Infection memory B memory B cell memory B cells natural Patient Poor primary antibody Reactions response risk SARS-CoV-2 SARS-COV-2 infection Spike protein Spike-specific antibody spike-specific T cell stimulate subsequent T cell response T cells third dose vaccination Vaccine vaccine dose were measured [DOI] 10.3390/cells10112915 PMC 바로가기 [Article Type] Article